公开(公告)号：EP4223757A1

公开(公告)日：2023-08-09

申请号：EP21874475.3

申请日：2021-09-28

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： XU, Huaqiang ,  LI, Jia ,  SHI, Jingjing ,  ZANG, Yi ,  SUN, Dandan ,  LIU, Mingliang ,  XIE, Rongrong ,  YOU, Erli ,  GAO, Lixin ,  TAN, Qian

IPC分类号： C07D471/08 ,  A61K31/46

摘要： A strong FXR small-molecule agonist, and a preparation method therefor and use thereof, the structure of the agonist being represented by formula (I). In the formula, each substituent is as defined in the description and the claims. The compound provided by the present invention has the advantages of high FXR agonist activity, simple synthesis, easily available raw materials and the like, and can be used for preparing medicines for treating FXR related diseases.

公开(公告)号：EP3957640A1

公开(公告)日：2022-02-23

申请号：EP20791301.3

申请日：2020-04-20

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： XU, Huaqiang ,  LI, Jia ,  SHI, Jingjing ,  ZANG, Yi ,  SUN, Dandan ,  LIU, Mingliang ,  XIE, Rongrong ,  YOU, Erli ,  GAO, Lixin ,  TAN, Qian

IPC分类号： C07D487/08 ,  A61P3/00 ,  A61P29/00 ,  A61P1/16 ,  A61P3/06 ,  A61P3/10 ,  A61K31/454 ,  A61K31/4245 ,  A61K31/439 ,  A61K31/55

摘要： An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases.

公开(公告)号：EP4458820A1

公开(公告)日：2024-11-06

申请号：EP22914967.9

申请日：2022-12-28

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LIU, Hong ,  LI, Jia ,  WANG, Jiang ,  ZANG, Yi ,  CHEN, Feiyang ,  GAO, Lixin ,  ZHAO, Jing ,  SUN, Dandan ,  WANG, Ke'an ,  JIANG, Hualiang ,  XIE, Rongrong

IPC分类号： C07D403/12 ,  C07D403/14 ,  C07D401/12 ,  C07D401/14 ,  C07D407/14 ,  C07C409/14 ,  C07D471/00 ,  C07D405/14 ,  C07K14/705 ,  C07K14/72 ,  A61K31/53 ,  A61P1/16 ,  A61P9/10 ,  A61P9/12 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P3/00 ,  A61P9/00

摘要： Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula(I), and a stereoisomer, a deuterated compound, a solvate, a metabolite, a pharmaceutically acceptable salt, a eutectic or a prodrug thereof, and a pharmaceutical composition thereof. Further provided in the present invention are a preparation method for the compound and the use thereof in the preparation of a drug for treating diseases mediated by thyroid hormone receptors. Related diseases include, but are not limited to, diseases such as non-alcoholic fatty liver diseases, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, lipid metabolism disorders, 1A type glycogen storage diseases, hypothyroidism and thyroid cancer.

公开(公告)号：EP3763716A1

公开(公告)日：2021-01-13

申请号：EP19763907.3

申请日：2019-03-08

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LIU, Hong ,  LI, Jia ,  WANG, Jiang ,  ZANG, Yi ,  LI, Jian ,  LI, Jingya ,  SUN, Dandan ,  JIANG, Hualiang ,  CHEN, Kaixian

IPC分类号： C07D495/04 ,  A61K31/55 ,  A61P1/16

摘要： Disclosed is use of a thiophene [3,2-d] pyrimidine-4-ketone compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.